380 related articles for article (PubMed ID: 9421376)
1. Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors.
Moens K; Flamez D; Van Schravendijk C; Ling Z; Pipeleers D; Schuit F
Diabetes; 1998 Jan; 47(1):66-72. PubMed ID: 9421376
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells.
Moens K; Berger V; Ahn JM; Van Schravendijk C; Hruby VJ; Pipeleers D; Schuit F
Diabetes; 2002 Mar; 51(3):669-75. PubMed ID: 11872665
[TBL] [Abstract][Full Text] [Related]
3. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.
Moens K; Heimberg H; Flamez D; Huypens P; Quartier E; Ling Z; Pipeleers D; Gremlich S; Thorens B; Schuit F
Diabetes; 1996 Feb; 45(2):257-61. PubMed ID: 8549871
[TBL] [Abstract][Full Text] [Related]
4. Glucagon receptors on human islet cells contribute to glucose competence of insulin release.
Huypens P; Ling Z; Pipeleers D; Schuit F
Diabetologia; 2000 Aug; 43(8):1012-9. PubMed ID: 10990079
[TBL] [Abstract][Full Text] [Related]
5. Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide.
Heller RS; Aponte GW
Am J Physiol; 1995 Dec; 269(6 Pt 1):G852-60. PubMed ID: 8572216
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide-1 is a physiological incretin in rat.
Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR
J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643
[TBL] [Abstract][Full Text] [Related]
7. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.
Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B
J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143
[TBL] [Abstract][Full Text] [Related]
8. Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype.
Flamez D; Gilon P; Moens K; Van Breusegem A; Delmeire D; Scrocchi LA; Henquin JC; Drucker DJ; Schuit F
Diabetes; 1999 Oct; 48(10):1979-86. PubMed ID: 10512362
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells.
Watanabe Y; Kawai K; Ohashi S; Yokota C; Suzuki S; Yamashita K
J Endocrinol; 1994 Jan; 140(1):45-52. PubMed ID: 8138751
[TBL] [Abstract][Full Text] [Related]
10. Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors.
Gromada J; Ding WG; Barg S; Renström E; Rorsman P
Pflugers Arch; 1997 Sep; 434(5):515-24. PubMed ID: 9242714
[TBL] [Abstract][Full Text] [Related]
11. Evidence that glucagon stimulates insulin secretion through its own receptor in rats.
Kawai K; Yokota C; Ohashi S; Watanabe Y; Yamashita K
Diabetologia; 1995 Mar; 38(3):274-6. PubMed ID: 7758872
[TBL] [Abstract][Full Text] [Related]
12. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin.
Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR
Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321
[TBL] [Abstract][Full Text] [Related]
13. Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets.
Kieffer TJ; Heller RS; Unson CG; Weir GC; Habener JF
Endocrinology; 1996 Nov; 137(11):5119-25. PubMed ID: 8895386
[TBL] [Abstract][Full Text] [Related]
14. Functional receptors for the insulinotropic hormone glucagon-like peptide-I(7-37) on a somatostatin secreting cell line.
Fehmann HC; Habener JF
FEBS Lett; 1991 Feb; 279(2):335-40. PubMed ID: 1672112
[TBL] [Abstract][Full Text] [Related]
15. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
[TBL] [Abstract][Full Text] [Related]
16. Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1.
Delmeire D; Flamez D; Hinke SA; Cali JJ; Pipeleers D; Schuit F
Diabetologia; 2003 Oct; 46(10):1383-93. PubMed ID: 13680124
[TBL] [Abstract][Full Text] [Related]
17. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide.
Kolligs F; Fehmann HC; Göke R; Göke B
Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808
[TBL] [Abstract][Full Text] [Related]
18. Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).
Green BD; Mooney MH; Gault VA; Irwin N; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
Metabolism; 2004 Feb; 53(2):252-9. PubMed ID: 14767880
[TBL] [Abstract][Full Text] [Related]
19. Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro.
Parkes DG; Pittner R; Jodka C; Smith P; Young A
Metabolism; 2001 May; 50(5):583-9. PubMed ID: 11319721
[TBL] [Abstract][Full Text] [Related]
20. Exendin-(9-39) is an inverse agonist of the murine glucagon-like peptide-1 receptor: implications for basal intracellular cyclic adenosine 3',5'-monophosphate levels and beta-cell glucose competence.
Serre V; Dolci W; Schaerer E; Scrocchi L; Drucker D; Efrat S; Thorens B
Endocrinology; 1998 Nov; 139(11):4448-54. PubMed ID: 9794451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
